E-MAIL UPDATES

Click here to join
our Electronic Communications.

Investors & Media

Whats new.

Press releases

Press releases.

Immutep Reports Positive Final Efficacy Data from TACTI-mel Trial in Melanoma

October 15th 2019
press releases

Immutep Announces Data Presentations at Upcoming Industry Conferences

October 10th 2019
press releases

Immutep Receives A$2.5 Million R&D Tax Incentive from French Government

October 10th 2019
press releases
more

Investor updates

Investor updates.

Investor Update - January 2019

January 31st 2019
investor updates

Investor Update - June 2018

June 19th 2018
investor updates

Investor Update - December 2017

December 21st 2017
investor updates
more

Analyst reports

Analyst reports.

goetzpartners securities - TACTI-mel final data confirm efficacy signals

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

October 15th 2019
analyst reports

goetzpartners securities - Positive interim analysis for TACTI-002

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

September 26th 2019
analyst reports

Maxim - GSK Initiates New Trial for IMP731-Derived Therapy, Triggers Milestone to Immutep

September 23rd 2019
analyst reports
more